Highlights Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
169.53 ^USD	+1.21%		+0.35%	+37.66%

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day

Highlights

Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	Dec. 05	CI
Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	Dec. 02	CI
Stockholm Bullets – Arise Soars on Takeover Bid	Nov. 27	FW
Traders Strap In, Again	Nov. 18
Zymeworks Commences Strategic Initiative for Licensed Products to Enhance Future Cash Flows	Nov. 18	MT
Beone Medicines Ltd. Announces Positive Phase 3 Results Support Ziihera® as Her2-Targeted Therapy-Of-Choice and Combination with Tevimbra and Chemotherapy as New Standard of Care in First-Line Her2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma	Nov. 17	CI
Top Midday Stories: Amazon to Sell Used Ford Vehicles on Website; Novo Nordisk Cuts Wegovy, Ozempic Prices	Nov. 17	MT
Jazz Pharmaceuticals plc Announces Positive Top-Line Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera®?	Nov. 17	CI
Jazz Pharmaceuticals plc Showcases New Clinical and Translational Data for Modeyso (Dordaviprone) in H3 K27M-Mutant Diffuse Midline Glioma at SNO 2025	Nov. 11	CI
Jazz Pharmaceuticals Q3 Non-GAAP Earnings, Revenue Rise; Raises 2025 Non-GAAP Earnings Guidance	Nov. 06	MT
(JAZZ) Jazz Pharmaceuticals Expects Full Year 2025 Adjusted EPS Range $7.65 - $8.45, vs. FactSet Est of $5.22	Nov. 05	MT
(JAZZ) Jazz Pharmaceuticals Expects Full Year 2025 Revenue Range $4.18 Billion - $4.28 Billion, vs. FactSet Est of $4.22 Billion	Nov. 05	MT
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Reports Q3 Revenue $1.13B, vs. FactSet Est of $1.11B	Nov. 05	MT
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q3 Adjusted EPS $8.13 per Share, vs. FactSet Est of $5.80	Nov. 05	MT
Jazz Pharmaceuticals Q3 revenue beats estimates	Nov. 05	RE
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on July 31, 2024.	Nov. 05	CI
Jazz Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 05	CI
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Full Year 2025	Nov. 05	CI
Jazz Pharmaceuticals to report third quarter financial results on November 5, 2025	Oct. 22	RE
Avadel, Jazz Pharmaceuticals Reach Settlement of Patent Dispute	Oct. 22	MT
Pharma Mar Gets $50 Million Milestone Payment After Securing US Nod for Small Cell Lung Cancer Drug	Oct. 15	MT
Pharma Mar receives $50 mln from Jazz Pharmaceuticals for FDA approval of Zepzelca in combination with Atezolizumab	Oct. 15	RE
FDA Approves Jazz Pharmaceuticals plc's Zepzelca (lurbinectedin) and Atezolizumab Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Oct. 02	CI
Jazz Pharma, Roche's combination therapy for lung cancer gets US approval	Oct. 02	RE
FDA approves lurbinectedin with atezolizumab/atezolizumab, hyaluronidase-tqjs for type of lung cancer	Oct. 02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Highlights

Filters